Caption Management’s Roivant Sciences ROIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.89M Sell
110,000
-109,800
-50% -$3.24M 0.02% 661
2026
Q1
$6.09M Buy
219,800
+58,813
+37% +$1.51M 0.04% 475
2025
Q4
$3.49M Buy
+160,987
New +$3.18M 0.02% 628
2025
Q3
Sell
-256,661
Closed -$3.18M 1985
2025
Q2
$2.89M Hold
256,661
0.03% 596
2025
Q1
$2.59M Buy
256,661
+106,323
+71% +$1.15M 0.02% 602
2024
Q4
$1.78M Sell
150,338
-19,662
-12% -$232K 0.02% 731
2024
Q3
$1.96M Buy
170,000
+45,670
+37% +$520K 0.03% 565
2024
Q2
$1.31M Buy
+124,330
New +$1.36M 0.02% 587
2023
Q4
Sell
-40,000
Closed -$390K 1618
2023
Q3
$467K Buy
+40,000
New +$452K 0.01% 946

Other funds holding ROIV

Caption Management's ROIV Position: Q2 2026 in Review

Caption Management reduced its Roivant Sciences (ROIV) stake by 50% in Q2 2026, selling an estimated $3.24M and leaving 110,000 shares worth $3.89M. The position accounts for 0.02% of the portfolio, ranked #661.

Caption Management first reported a position in ROIV in Q3 2023 and has held it in 9 quarters since. The position peaked at $6.09M in Q1 2026. 500 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Caption Management held 110,000 shares of Roivant Sciences worth $3.89M as of Q2 2026.
  • Caption Management sold 109,800 Roivant Sciences shares in Q2 2026, an estimated $3.24M.
  • Roivant Sciences made up 0.02% of Caption Management's portfolio in Q2 2026, its #661 holding.
  • Caption Management first reported a position in Roivant Sciences in Q3 2023 and has held it in 9 quarters since.
  • Caption Management's Roivant Sciences position peaked at $6.09M in Q1 2026.
  • 500 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.